Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myeloid, Acute 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 61Myelodysplastic Syndromes 52Recurrence 37Leukemia, Lymphocytic, Chronic, B-Cell 37Multiple Myeloma 36Lymphoma, Non-Hodgkin 35Lymphoma 34Lymphoma, B-Cell 29Hematologic Neoplasms 28Lymphoma, Follicular 24Lymphoma, Large B-Cell, Diffuse 23Lymphoma, Mantle-Cell 22Leukemia 22Melanoma 21Lymphoma, B-Cell, Marginal Zone 20Myeloproliferative Disorders 19Leukemia, Myelogenous, Chronic, BCR-ABL Positive 19Leukemia, Biphenotypic, Acute 18Hodgkin Disease 18Ovarian Neoplasms 17Burkitt Lymphoma 17Pancreatic Neoplasms 16Neoplasms 13Neoplasm Metastasis 12Leukemia, Myelomonocytic, Chronic 12Colorectal Neoplasms 11Anemia, Refractory, with Excess of Blasts 11Stomach Neoplasms 10Carcinoma, Non-Small-Cell Lung 10

Interventions

Magnetic Resonance Spectroscopy 8Specimen Handling 7Biopsy 6X-Rays 5Phantoms, Imaging 5Temozolomide 4Nuclear Medicine Department, Hospital 4Nivolumab 4Carboplatin 4selpercatinib 3larotrectinib 3Topotecan 3Etoposide 3Cyclophosphamide 3Cisplatin 3Automobiles 3tazemetostat 2pembrolizumab 2erdafitinib 2entrectinib 2ensartinib 2cabozantinib 2Vincristine 2Surveys and Questionnaires 2Radiotherapy 2Radiosurgery 2Radiation 2Positron-Emission Tomography 2Paclitaxel 2ONC206 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Central Nervous System Neoplasms × fludarabine × 1 year × Clear all
NCT07390539 2026-02-05

B7-H3.CD28Z.CART in CNS Neoplasms

Dana-Farber Cancer Institute

Phase 1 Not yet recruiting
70 enrolled
CNS

Brain Neoplasms, Ependymoma, Medulloblastoma, Meningeal Neoplasms, Pinealoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡